Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
O-PrEP Stage 1: Optimizing PrEP Regimens for Pregnant Women
NCT06435026Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Jun 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (3 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Tenofovir diphosphate concentration in peripheral blood mononuclear cells. Started Jun 2024; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06435026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06435026.